What is TriSalus Life Sciences, Inc.'s market cap?

TriSalus Life Sciences, Inc. (TLSI) has a market capitalization of $265.3M and trades on NASDAQ.

What is TriSalus Life Sciences, Inc.'s revenue and profitability?

TriSalus Life Sciences, Inc. generated $44.9M in trailing twelve-month revenue with a net loss of $27.3M, representing a net margin of -60.9%. Gross margin stands at 85.1%, with free cash flow of -$20.3M. These figures are based on the Q1 2026 filing.

Who are TriSalus Life Sciences, Inc.'s competitors?

TriSalus Life Sciences, Inc.'s key competitors include Boston Scientific, AngioDynamics, United Therapeutics Corp, and others. These companies compete in similar markets and product categories.

What subsidiaries does TriSalus Life Sciences, Inc. have?

TriSalus Life Sciences, Inc.'s subsidiaries include MedTech Acquisition Corp..

Where is TriSalus Life Sciences, Inc. headquartered?

TriSalus Life Sciences, Inc. is headquartered in United States of America. It has been publicly traded since 2023.

TriSalus Life Sciences, Inc.

TLSI

TriSalus Life Sciences is an oncology-focused medical technology company dedicated to improving treatment outcomes for patients with solid tumors.

Market cap

$265.32M+57.7%

Revenue$44.9M+39.6%

Net income-$27.3M-0.4%

Free cash flow-$20.3M+42.8%

EPS (diluted)-$1.32-17.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$8.9MMiss by $1.3M EPS-$0.33Miss by $0.17

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$10.3M

EPS estimate-$0.16

Financials

Q1 2026

Income statement

See full

Revenue$8.9M-2.9%

Gross profit$7.7M0.0%

Operating income-$8.4M-14.8%

Net income$1.5M+115%

EPS (diluted)$0.03+108%

Balance sheet

See full

Cash & equivalents$56.6M+324%

Total debt$33.1M+4.4%

Total equity$12.8M+137%

Total assets$71.0M+148%

Cash flow

See full

Operating cash flow-$6.5M-44.0%

CapEx$141.0K-81.3%

Free cash flow-$6.6M-26.0%

Valuation & ratios

Valuation

See full

Market cap$265.32M+57.7%

Enterprise value$241.85M+35.7%

P/S5.9×+1.1×

Profitability

See full

Gross margin85.1%-0.5pp

Operating margin-62.4%-16.8pp

Net margin-60.9%-13.4pp

FCF margin-45.2%-16.8pp

Returns & leverage

See full

Debt / equity2.6×—

Current ratio5.8×+3.6×

Competitors

By market cap

Boston Scientific$67.6B-56.8%

United Therapeutics$26.3B+95.5%

LQD

Liquidia Corporation$7.5B+343%

Tactile Systems Technology$626.2M+156%

AngioDynamics$564.6M+52.4%

Delcath Systems$412.2M+3.7%

TriSalus Life Sciences, Inc.$265.3M+53.6%

InfuSystem Holdings$188.9M+52.6%

By revenue growth

LQD

Liquidia Corporation+1,937%

Delcath Systems+68.0%

TriSalus Life Sciences, Inc.+39.6%

Boston Scientific+17.4%

Tactile Systems Technology+17.2%

AngioDynamics+9.5%

United Therapeutics+5.9%

InfuSystem Holdings+3.5%

By net margin

United Therapeutics40.61%+0.2pp

Boston Scientific17.26%+5.7pp

Tactile Systems Technology5.91%+0.4pp

InfuSystem Holdings5.56%+3.2pp

Delcath Systems1.51%+52.9pp

AngioDynamics-11.48%+0.1pp

TriSalus Life Sciences, Inc.-60.85%+23.8pp

LQD

Liquidia Corporation-176.24%+896pp

Profile

TriSalus Life Sciences is an oncology-focused medical technology company dedicated to improving treatment outcomes for patients with solid tumors. The company integrates proprietary drug delivery technology with standard-of-care therapies and its own investigational immunotherapeutic to overcome high intratumoral pressure and off-target delivery challenges.

Competitive position

A specialized player focusing on the intersection of interventional oncology devices and immunotherapy to solve drug penetration issues in desmoplastic tumors.

GeographiesUnited States

Customer segmentsSpecialized healthcare providers, Tertiary care centers, Clinical research organizations

Business modelMedical device manufacturing, Drug-device combination development, R&D intensive

SuppliersSpecialized medical-grade component manufacturers, Contract research organizations, Raw material suppliers for immunotherapeutics

CustomersInterventional oncologists, Surgical oncologists, Specialty hospitals

CountryUnited States of America

Listed2023

CEOMary T. Szela

SectorHealthcare

IndustryMedical - Devices

Websitetrisaluslifesci.com

FilingsSEC EDGAR

Ask your AI about TriSalus Life Sciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s market cap?: TriSalus Life Sciences, Inc. (TLSI) has a market capitalization of $265.3M and trades on NASDAQ.
What is TriSalus Life Sciences, Inc.'s revenue and profitability?: TriSalus Life Sciences, Inc. generated $44.9M in trailing twelve-month revenue with a net loss of $27.3M, representing a net margin of -60.9%. Gross margin stands at 85.1%, with free cash flow of -$20.3M. These figures are based on the Q1 2026 filing.
Who are TriSalus Life Sciences, Inc.'s competitors?: TriSalus Life Sciences, Inc.'s key competitors include Boston Scientific, AngioDynamics, United Therapeutics Corp, and others. These companies compete in similar markets and product categories.
What subsidiaries does TriSalus Life Sciences, Inc. have?: TriSalus Life Sciences, Inc.'s subsidiaries include MedTech Acquisition Corp..
Where is TriSalus Life Sciences, Inc. headquartered?: TriSalus Life Sciences, Inc. is headquartered in United States of America. It has been publicly traded since 2023.